XML 79 R64.htm IDEA: XBRL DOCUMENT
v3.25.0.1

License, Collaborative and Employment Agreements and Commitments (Details) |  |  |  |  |  |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 13, 2024 USD ($) | Dec. 14, 2023 USD ($) shares | Dec. 15, 2022 USD ($) shares | Aug. 07, 2019 USD ($) | Feb. 15, 2016 EUR (€) | Dec. 19, 2012 USD ($) | Nov. 28, 2012 USD ($) shares | Jan. 31, 2023 USD ($) | Nov. 30, 2017 USD ($) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2023 EUR (€) | Dec. 31, 2022 USD ($) | Dec. 31, 2015 shares
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual base salary | $ 667,536 | $ 644,963 | $ 614,250 |  |  |  |  |  |  |  |  |  |  |
Operating lease cost |  |  |  |  |  |  |  |  |  | $ 631,000 | $ 624,000 |  |  |
Non cash addition of right of use assets |  |  |  |  |  |  |  |  |  | 937,000 |  |  |  |
Saint Joan de deu collaboration and license agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment to be made subject to third party economic aid | € |  |  |  |  | € 500,000 |  |  |  |  |  |  |  |  |
Payment to be made after clinical trial | € |  |  |  |  | € 320,000 |  |  |  |  |  |  |  |  |
Maximum period for payment clinical trial |  |  |  |  | 4 years |  |  |  |  |  |  |  |  |
Licensing Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual payments due under license agreement |  |  |  |  |  | $ 50,000 |  |  |  |  |  |  |  |
Final payment due under license agreement |  |  |  |  |  | 25,000 |  |  |  |  |  |  |  |
Steven A. Shallcross |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash bonus paid as per employee agreement | $ 200,000 | $ 350,000 | $ 385,000 |  |  |  |  |  |  |  |  |  |  |
Share-based payment award, options, grants in period, gross | shares |  | 700,000 | 475,000 |  |  |  |  |  |  |  |  |  |  |
Prev Abr Llc |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional cash payment for license agreement |  |  |  |  |  |  | $ 235,000 |  |  |  |  |  |  |
Unregistered shares issued to license agreement | shares |  |  |  |  |  |  | 17,858 |  |  |  |  |  |  |
Additional consideration payable |  |  |  |  |  |  | 50% in cash and 50% in the Company’s stock |  |  |  |  |  |  |
Options to be received common stock shares | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 18,724
Phase I Clinical Trials |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | 50,000 |  |  |  |  |  |  |  |
Phase III Clinical Trials |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | 100,000 |  |  |  |  |  |  |  |
NDA Submission In US |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | 250,000 |  |  |  |  |  |  |  |
European Medicines Agency Approval |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | 100,000 |  |  |  |  |  |  |  |
Regulatory Approval In Asian Country |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | 100,000 |  |  |  |  |  |  |  |
Clinical Trial Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated research costs |  |  |  | $ 3,200,000 |  |  |  |  |  |  |  |  |  |
Payments for other fees |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,100,000 |
Exclusive Option License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Extend option period |  |  |  |  |  |  |  | $ 7,500 |  |  |  |  |  |
Collaboration and license agreement | Saint Joan de deu collaboration and license agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of option Fee | € |  |  |  |  |  |  |  |  |  |  |  | € 25,000 |  |
Technology Transfer Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amounts incurred for termination of agreement |  |  |  |  |  |  |  |  |  | 0 | 0 |  |  |
ICO Marketing License |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amounts incurred for termination of agreement |  |  |  |  |  |  |  |  |  | 0 | 0 |  |  |
IDIBELL/ICO License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amounts incurred for termination of agreement |  |  |  |  |  |  |  |  |  | 0 | 0 |  |  |
University of Texas Austin Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amounts incurred for termination of agreement |  |  |  |  |  |  |  |  |  | 0 | 0 |  |  |
Consulting Fees |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amounts incurred for termination of agreement |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 |  |  |
Payments for other fees |  |  |  |  |  |  |  |  | $ 4,500,000 |  |  |  |  |
First Year |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research agreement fixed fee |  |  |  |  |  | 303,000 |  |  |  |  |  |  |  |
Second Year |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research agreement fixed fee |  |  |  |  |  | 316,000 |  |  |  |  |  |  |  |
Third Year |  |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research agreement fixed fee |  |  |  |  |  | $ 329,000 |  |  |  |  |  |  |  |

X
- Definition The amount of additional cash payment for license agreement. + References No definition available. + Details
Name: | tovx_AdditionalCashPaymentForLicenseAgreement
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Description related to additional consideration payable. + References No definition available. + Details
Name: | tovx_AdditionalConsiderationPayable
Namespace Prefix: | tovx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amounts incurred by the company under the of collaborative arrangements. + References No definition available. + Details
Name: | tovx_CollaborativeArrangementAmountsIncurred
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of estimated research services cost provided. + References No definition available. + Details
Name: | tovx_EstimatedResearchCosts
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of annual payments due under the license agreement. + References No definition available. + Details
Name: | tovx_LicenseAgreementAnnualPaymentsDue
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of the final payment due under the license agreement. + References No definition available. + Details
Name: | tovx_LicenseAgreementFinalPaymentDue
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | tovx_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems
Namespace Prefix: | tovx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of years within which payment has to be made under the agreement + References No definition available. + Details
Name: | tovx_MaximumPeriodForPaymentClinicalTrial
Namespace Prefix: | tovx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition A milestone payment is an authority payment made to a contractor which is linked to the contractor delivering a service or commodity such that, should the agreement be terminated at the point of payment. + References No definition available. + Details
Name: | tovx_MilestonePayment
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of non cash addition to right of use assets. + References No definition available. + Details
Name: | tovx_NonCashAdditionOfRightOfUseAssets
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition It Represents options to be received common stock shares reporting period. + References No definition available. + Details
Name: | tovx_OptionsToBeReceivedCommonStockShares
Namespace Prefix: | tovx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount paid for the extension of option period. + References No definition available. + Details
Name: | tovx_PaymentForExtensionOfOption
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of payment of option fee during the reporting period. + References No definition available. + Details
Name: | tovx_PaymentOfOptionFee
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount to be paid under the agreement after the clinical trials + References No definition available. + Details
Name: | tovx_PaymentToBeMadeAfterClinicalTrial
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Payment to be made to the foundation subject to private or public economic aid that third parties may grant to the institution. + References No definition available. + Details
Name: | tovx_PaymentToBeMadeSubjectToThirdPartyEconomicAid
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of research and development costs incurred for a fixed-price, all payable in quarterly installments. + References No definition available. + Details
Name: | tovx_ResearchAgreementFixedFee
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of shares issued during the period for license agreement. + References No definition available. + Details
Name: | tovx_UnregisteredSharesIssuedToLicenseAgreement
Namespace Prefix: | tovx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of commitment made to pay deferred cash remuneration. + References No definition available. + Details
Name: | us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details
Name: | us-gaap_OperatingLeaseCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash outflow for fees classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments of cash to employees, including wages and salaries, during the current period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details
Name: | us-gaap_PaymentsToEmployees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Gross number of share options (or share units) granted during the period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=tovx_SaintJoanDeDeuCollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=tovx_StevenAShallcrossMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tovx_PrevAbrLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_PhaseIClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_PhaseIiiClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_NdaSubmissionInUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_EuropeanMedicinesAgencyApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_RegulatoryApprovalInAsianCountryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_ClinicalTrialAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_ExclusiveOptionLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_TechnologyTransferAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_IcoMarketingLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_IdibellIcoLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_UniversityOfTexasAustinAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tovx_ConsultingFeesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | tovx_QuarterlyInstallmentsPaymentPeriodAxis=tovx_FirstYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | tovx_QuarterlyInstallmentsPaymentPeriodAxis=tovx_SecondYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | tovx_QuarterlyInstallmentsPaymentPeriodAxis=tovx_ThirdYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |